• A Corrigendum to this article was published on 24 January 2018

This article has been updated

Abstract

Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 24 January 2018

    In the version of this article originally published, the name of one of the authors, Peter Schulz-Knappe, was incorrectly given as Peter Schulze-Knappe. In addition, Mark Coles and James Butler were erroneously omitted from the list of members of the RA-MAP Consortium. These errors have now been corrected in the PDF and HTML versions of the article.

References

  1. 1.

    & Drug discovery alliances. Nat. Rev. Drug Discov. 4, 807–808 (2005).

  2. 2.

    et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat. Rev. Drug Discov. 8, 701–708 (2009).

  3. 3.

    , , & Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data. Front. Pharmacol. 7, 461 (2016).

  4. 4.

    , , & Systems medicine for lung diseases: phenotypes and precision medicine in cancer, infection, and allergy. Methods Mol. Biol. 1386, 119–133 (2016).

  5. 5.

    et al. Big and disparate data: considerations for pediatric consortia. Curr. Opin. Pediatr. 29, 231–239 (2017).

  6. 6.

    “A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science. Life Sci. Soc. Policy 13, 7 (2017).

  7. 7.

    Opening up the ivory tower. Cell 129, 847–850 (2007).

  8. 8.

    , , & Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med. 15, 502–507 (2009).

  9. 9.

    , , , & What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med. Ethics 14, 55 (2013).

  10. 10.

    Association of the British Pharmaceutical Industry. Stratified medicine in the NHS: an assessment of the current landscape and implementation challenges for non-cancer applications. ABPI (2014).

  11. 11.

    Association of the British Pharmaceutical Industry. The stratification of disease for personalised medicines. Research driven recommendations to strengthen a unified UK strategy through a stakeholder alliance. ABPI (2014).

  12. 12.

    Academy of Medical Sciences. Stratified, personalised or P4 medicine: a new direction for placing the patient at the centre of healthcare and health education. Academy of Medical Science s (2015).

  13. 13.

    UK Trade and Investment. Unlock your global business potential. UK stratified medicine. GOV.UK (2013).

  14. 14.

    Medical Research Council. The Medical Research Council stratified medicine research initiatives. MRC (2017).

  15. 15.

    & Genomics and medicine. Dissecting human disease in the postgenomic era. Science 291, 1224–1229 (2001).

  16. 16.

    , & Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol. 3, 124 (2007).

  17. 17.

    & Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat. Genet. 33, 228–237 (2003).

  18. 18.

    & Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95–108 (2005).

  19. 19.

    et al. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat. Rev. Drug Discov. 16, 70 (2017).

  20. 20.

    , & Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat. Rev. Genet. 17, 392–406 (2016).

  21. 21.

    , & Computational solutions for omics data. Nat. Rev. Genet. 14, 333–346 (2013).

  22. 22.

    , & Revolutionizing medicine in the 21st century through systems approaches. Biotechnol. J. 7, 992–1001 (2012).

  23. 23.

    Institute for Safe Medication Practices. The five rights: a destination without a map. Institute for Safe Medication Practices (2007).

  24. 24.

    , & Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nat. Rev. Rheumatol. 12, 63–68 (2016).

  25. 25.

    , , , & Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 95, e4975 (2016).

  26. 26.

    & End-joining, translocations and cancer. Nat. Rev. Cancer 13, 443–454 (2013).

  27. 27.

    Mechanisms of human lymphoid chromosomal translocations. Nat. Rev. Cancer 16, 387–398 (2016).

  28. 28.

    et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

  29. 29.

    , , & Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63–72 (1996).

  30. 30.

    et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

  31. 31.

    et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

  32. 32.

    , & Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 36, 179–190 (2017).

  33. 33.

    & Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Arch. 471, 209–219 (2017).

  34. 34.

    , & Immune checkpoint inhibitor therapy: what line of therapy and how to choose? Curr. Treat. Options Oncol. 18, 33 (2017).

  35. 35.

    Medical Research Council. MRC Strategic Review of Human Immunology. MRC (2007).

  36. 36.

    et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann. Rheum. Dis. 71, 638–641 (2012).

  37. 37.

    Innovative Medicines Initiative. The IMI funding model. IMI (2017).

  38. 38.

    , & Adjusting batch effects in microarray expression data using Empirical Bayes methods. Biostatistics 8, 118–127 (2007).

  39. 39.

    et al. SmartR: an open-source platform for interactive visual analytics for translational research data. Bioinformatics 33, 2229–2231 (2017).

Download references

Acknowledgements

The programme of research described in this Perspectives article was funded by the Medical Research Council (MRC), UK. The RA-MAP Consortium would particularly like to thank members of the MRC Immunity and Inflammation Stratified Medicine Steering Group and officers of the MRC, who have supported the work of the RA-MAP Consortium with unbridled enthusiasm.

Author information

Affiliations

  1. Andrew P. Cope is at the Centre for Inflammation Biology and Cancer Immunology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Great Maze Pond, London, SE1 1UL, UK.

    • Andrew P. Cope
  2. M.R.B. is at Queen Mary University of London, UK.

    • Michael R. Barnes
  3. A.B., M.B. and R.R. are at GlaxoSmithKline.

    • Alexandra Belson
    • , Michael Binks
    •  & Ravi Rao
  4. S.B., A.W.P. and J.D.I. are at Newcastle University, UK.

    • Sarah Brockbank
    • , Ayako Wakatsuki Pedersen
    •  & John D. Isaacs
  5. F.B.-C., A.R. and D.V. are at Janssen.

    • Francisco Bonachela-Capdevila
    • , Anthony Rowe
    •  & Denny Verbeeck
  6. C.C. is at Pfizer.

    • Claudio Carini
  7. B.A.F. is at the University of Birmingham, UK.

    • Benjamin A. Fisher
  8. C.S.G., I.B.M. and D.P. are at the University of Glasgow, UK.

    • Carl S. Goodyear
    • , Iain B. McInnes
    •  & Duncan Porter
  9. P.E., M.F.M. and F.P. are at the University of Leeds, UK.

    • Paul Emery
    • , Michael F. McDermott
    •  & Frederique Ponchel
  10. M.R.E. is at University College London, UK.

    • Michael R. Ehrenstein
  11. N.G. and G.P. are at UCB Pharma.

    • Neil Gozzard
    •  & Gerry Parker
  12. R.H. is at Elsai.

    • Ray Harris
  13. S.H. and C.L. are at AstraZeneca.

    • Sally Hollis
    •  & Catharina Lindholm
  14. S.K. and M.L. are at Abbvie.

    • Sarah Keidel
    •  & Marc Levesque
  15. C.M.M. is at Roche.

    • Christopher M. Mela
  16. S.R. is at Grunenthal.

    • Simon Read
  17. P.S.-K. is at Protagen AG.

    • Peter Schulz-Knappe
  18. M.A.S. is at MedImmune.

    • Matthew A. Sleeman
  19. D.S. is at the University of Manchester, UK.

    • Deborah Symmons
  20. P.C.T. is at the University of Oxford, UK.

    • Peter C. Taylor
  21. B.T. is at the University of Cambridge, UK.

    • Brian Tom
  22. W.T. is at Amgen.

    • Wayne Tsuji

Consortia

  1. The RA-MAP Consortium

Authors

  1. Search for Andrew P. Cope in:

  2. Search for Michael R. Barnes in:

  3. Search for Alexandra Belson in:

  4. Search for Michael Binks in:

  5. Search for Sarah Brockbank in:

  6. Search for Francisco Bonachela-Capdevila in:

  7. Search for Claudio Carini in:

  8. Search for Benjamin A. Fisher in:

  9. Search for Carl S. Goodyear in:

  10. Search for Paul Emery in:

  11. Search for Michael R. Ehrenstein in:

  12. Search for Neil Gozzard in:

  13. Search for Ray Harris in:

  14. Search for Sally Hollis in:

  15. Search for Sarah Keidel in:

  16. Search for Marc Levesque in:

  17. Search for Catharina Lindholm in:

  18. Search for Michael F. McDermott in:

  19. Search for Iain B. McInnes in:

  20. Search for Christopher M. Mela in:

  21. Search for Gerry Parker in:

  22. Search for Simon Read in:

  23. Search for Ayako Wakatsuki Pedersen in:

  24. Search for Frederique Ponchel in:

  25. Search for Duncan Porter in:

  26. Search for Ravi Rao in:

  27. Search for Anthony Rowe in:

  28. Search for Peter Schulz-Knappe in:

  29. Search for Matthew A. Sleeman in:

  30. Search for Deborah Symmons in:

  31. Search for Peter C. Taylor in:

  32. Search for Brian Tom in:

  33. Search for Wayne Tsuji in:

  34. Search for Denny Verbeeck in:

  35. Search for John D. Isaacs in:

Contributions

A.P.C., M.R.B. and J.D.I. wrote the manuscript. A.P.C., S.B., F.B.-C. and A.W.P. researched data for the article. A.P.C., M.R.B., A.B., M.B., S.B., F.B.-C., B.A.F., C.S.G., P.E., M.E.R., N.G., R.H., S.H., M.F.M., I.B.M., S.R., A.W.P., F.P., D.P., R.R., A.R., M.A.S., D.S., B.T. and J.D.I. provided substantial contributions to discussions of content. A.P.C., M.R.B., A.B., S.B., F.B.-C., C.C., B.A.F., C.S.G., M.E.R., N.G., R.H., S.H., S.K., M.L., C.L., M.F.M., I.B.M., C.M.M., G.P., S.R., A.W.P., F.P., D.P., A.R., P.S.-K., M.A.S., D.S., P.C.T., B.T., W.T., D.V. and J.D.I. reviewed and/or edited the manuscript before submission.

Competing interests

A.P.C. declares that he has acted as a consultant for or received honoraria from BMS, Eisai, GSK, Janssen and Roche. For a full list of competing interests for all co-authors, see Supplementary information S6 (table).

Corresponding author

Correspondence to Andrew P. Cope.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (figure)

    The RA-MAP Consortium

  2. 2.

    Supplementary information S2 (figure)

    The RA-MAP Research Programme

  3. 3.

    Supplementary information S3 (figure)

    Project management and reporting lines

  4. 4.

    Supplementary information S4 (figure)

    RA-MAP core technologies

  5. 5.

    Supplementary information S5 (figure)

    Managing 'big data'

  6. 6.

    Supplementary information S6 (table)

    Contributing authors and their competing interests

  7. 7.

    Supplementary information S7 (box)

    RA-MAP Consortium Membership (2012 – current)

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2017.200

Further reading